Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Enteric-coated Mycophenolate Sodium vs. Mycophenolate Mofetil in de Novo Chinese Renal Transplant Recipients
NCT00149903Phase 3Completed
- Sponsor
- Novartis
- Start
- Jan 2005
- Primary completion
- Jun 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of mycophenolate sodium in kidney transplant rejection (2 arms), sponsored by Novartis. Primary endpoint: Incidence of biopsy proven acute rejection, graft loss, or death at 6 months. Started Jan 2005; status: completed.
02
Drugs
mycophenolate sodium
03
Conditions
kidney transplant rejection
Beyond the preview
Go deeper on NCT00149903.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00149903.